Bayer is driven by science and the courage to imagine the unimaginable, aiming to create meaningful medicines that address high unmet medical needs. Bayer R&D's early innovation activities concentrate on four key areas, including oncology, cardiovascular-renal, neurology and rare diseases, and immunology. The focus areas are designed to drive leadership and accelerate growth through a competitive early-stage pipeline. Bayer's multi-faceted innovation engine encompasses both internal and external activities. The company emphasizes the importance of collaborations with academia and platform companies to foster innovation. Based on deep disease understanding, collaboration, and by leveraging a diverse drug modality mix (including protein therapeutics, small molecules, genetic medicines, cell therapy, and chemoproteomics), Bayer R&D explores innovative and highly differentiated therapy approaches to best address the medical need of patients.